Quantcast

Latest Avastin Stories

2008-10-06 15:00:41

Blockbuster cancer drug Avastin has suffered a setback, failing to improve overall survival when added to Tarceva in a Phase III trial for second-line advanced non-small cell lung cancer. However, there may still be a future for the drug combination within this indication, assuming data from a Phase III trial in the maintenance setting prove more positive. The Phase III study, known as BeTa Lung, was a randomized, double blinded study comparing the second-line combination of Avastin...

2008-10-06 09:00:09

Genentech and OSI Pharmaceuticals have announced that a randomized Phase III study evaluating Avastin in combination with Tarceva in patients with advanced non-small cell lung cancer whose disease had progressed following platinum-based chemotherapy did not meet its primary endpoint of improving overall survival compared to Tarceva in combination with placebo. However, there was clear evidence of clinical activity with improvements in the secondary endpoints of progression-free survival and...

2008-10-06 03:00:07

Genentech, Inc. (NYSE:DNA) and OSI Pharmaceuticals, Inc. (Nasdaq:OSIP) today announced that a randomized Phase III study (BeTa Lung) evaluating Avastin(R) (bevacizumab) in combination with Tarceva(R) (erlotinib) in patients with advanced non-small cell lung cancer (NSCLC) whose disease had progressed following platinum-based chemotherapy did not meet its primary endpoint of improving overall survival compared to Tarceva in combination with placebo. However, there was clear evidence of...

2008-10-01 00:10:00

By DOMINIC JEFF Herald Reporter A plymouth woman fighting to get a life-extending drug on the NHS has launched a petition for people to support her appeal. Stephanie Chouette, aged 34, has breast cancer which has spread to her vertebrae and liver, and has only a few months to live. The drug, Avastin, would probably double her life expectancy but is only available in the UK if patients can show "exceptional circumstances". A request by Stephanie's doctor for her to have Avastin, which...

2008-09-29 09:00:58

SCOTTSDALE, Ariz., Sept. 29 /PRNewswire/ -- NeoVista, Inc. made public yesterday 18-month data from the company's Phase II feasibility study examining its novel epiretinal brachytherapy for treatment of the wet form of age-related macular degeneration (AMD) at the 41st Scientific Meeting of the Retina Society. The long-term data from the study, which was initiated to test the safety and efficacy of their therapy when used in conjunction with Avastin(R) (bevacizumab), showed a marked...

2008-09-16 09:00:53

Roche has announced that the final analysis of the Avastin in lung study in patients with advanced lung cancer has shown that not only did the drug significantly slow down the disease progression, it also enabled some patients to survive for over one year, the longest survival ever reported in patients with this advanced disease. The Phase III Roche-sponsored AVAiL study in patients with previously untreated, advanced non-small cell lung cancer (NSCLC), has confirmed that Avastin...

2008-08-29 03:00:10

WASHINGTON - What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing $60 per treatment and the other $2,000? In the case of Genentech Inc., nothing. The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance - or cooperate with - a National Eye Institute study comparing the...

2008-08-28 21:00:03

What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000? In the case of Genentech Inc., nothing. The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance - or cooperate with - a National Eye Institute study comparing the...

08437c12a373722e7aef749237ef41041
2008-08-28 09:05:00

By Kevin Freking Associated Press What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000? In the case of Genentech Inc., nothing. The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance -- or cooperate with -- a National Eye...

2008-08-08 09:00:28

The UK's cost-effectiveness watchdog NICE has delivered another blow to the developers of targeted cancer therapies by recommending against the use of four new kidney cancer drugs in the UK. This recommendation suggests that NICE is likely to look unfavorably on a number of other targeted therapies in development, severely limiting future growth of the targeted cancer therapies market in the UK. In its preliminary guidance report on a number of new targeted cancer therapies, the UK's...


Word of the Day
callithump
  • A somewhat riotous parade, accompanied with the blowing of tin horns, and other discordant noises; also, a burlesque serenade; a charivari.
'Callithump' is a back-formation of 'callithumpian,' a 'fanciful formation' according to the Oxford English Dictionary. However, the English Dialect Dictionary, says 'Gallithumpians' is a Dorset and Devon word from the 1790s that refers to 'a society of radical social reformers' or 'noisy disturbers of elections and meetings.'
Related